Experienced, respected leaders in their fields help position Adaptive for strong growth.
SEATTLE, WA, September 29, 2011 – Adaptive TCR Corporation, a leading provider of online solutions for large scale immune system profiling under the brand name immunoSEQ, announced today several high profile additions to its Board of Directors, Corporate Advisory Board, and Scientific Advisory Board.
“These new board members will further diversify the wealth of experience and deep industry knowledge that our directors already bring to this company,” said Chad Robins, CEO and President of Adaptive TCR Corporation. “Each individual is a respected and an accomplished leader in their fields, and I look forward to working with all the directors as we continue to grow and provide ground-breaking technology to the research community.”
Board of Directors
Joining the Board of Directors will be Dr. Lee Huntsman, President Emeritus of the University of Washington and Chairman of the Washington State Life Sciences Discovery Fund, and Dr. Arnold Levine, Systems Biology Professor at the Institute for Advanced Study in Princeton, who discovered the p53 tumor suppressor protein.
“Lee brings a broad-based perspective on management, and Arnie, who has been with Adaptive since early on as a scientific advisor, will continue to offer his insight and wide-ranging expertise,” added Robins.
Huntsman and Levine join current Adaptive board members Dr. Andris Zoltners, Founder and Chairman of ZS Associates, Craig Weissman, former Chief Technology Officer at Salesforce.com, and Robins.
Corporate Advisory Board
Dr. Carol Gallagher, former President and CEO of Calistoga Pharmaceuticals, and Stewart Parker, the CEO of the Infectious Disease Research Institute in Seattle, WA., join the Corporate Advisory Board.
“Carol has challenged us to think big and is an insider in the biopharmaceutical world, while Stewart brings an understanding of strong management and is an excellent judge of character,” described Robins.
Gallagher and Parker join board members Graham C. Allen, President and CEO of Sloan Valve Company, Matt Kahn, Executive Vice President at LRP Publications, Peter Keane, Senior Vice President at Pulte Homes, Dr. Richard Mitchell, Director of Business Development at the Fred Hutchinson Cancer Research Center, and Josh Rosen, Partner at Freshford Capital Management.
Scientific Advisory Board
Dr. Cassian Yee, a member of the Fred Hutchinson Cancer Research Center, where he focuses primarily on cancer immunotherapy, joins the Scientific Advisory Board.
“We’re extremely fortunate to have someone like Cassian on the board,” said Robins. “He’s a true leader in the field of cancer immunotherapy, which is a key target for Adaptive.”
Yee joins board members Dr. Gerald T. Nepom, Director at the Benaroya Research Institute, Dr. Jay Shendure, Assistant Professor of Genome Sciences at the University of Washington, and Dr. Edus Houston Warren, Associate Professor in the Department of Medicine at the University of Washington.
About Adaptive TCR Corporation and immunoSEQ™
Adaptive TCR Corporation, headquartered in Seattle, WA, develops, commercializes and supports online solutions for large scale immune system profiling. Adaptive TCR’s proprietary technologies were developed at the Fred Hutchinson Cancer Research Center by co-founders Harlan Robins, PhD and Chris Carlson, PhD. The technologies include a DNA amplification chemistry that can generate many millions of T cell receptor sequences from a single DNA sample, and a bioinformatics software suite designed specifically to manage the large amounts of data resulting from a typical assay. These technologies are marketed for life science research applications under the brand name immunoSEQ and immunoSEQ Analyzer™. The company began commercial operations in 2009 under the leadership of Chad Robins, CEO.
